Bezlotoxumab: A Review in Preventing Clostridium Difficile Infection Recurrence

Emma D Deeks
Compliance with Ethical Standards Funding: The preparation of this review was not supported by any external funding. Conflicts of interest: Emma Deeks is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest. Additional information about this Adis Drug Review can be found here. Abstract Bezlotoxumab (Zinplava™) is a fully human monoclonal antibody against Clostridium difficile toxin B indicated for the prevention of C. difficile infection (CDI)...
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.